Skip to main content
. 2018 Aug 20;7(3):CNS23. doi: 10.2217/cns-2018-0010

Table 2. . The conditional survival rates estimated by the integrated survival model.

Survival to year given 2-year survival TTFields with maintenance TMZ Maintenance TMZ alone
Year 2 100% 100%

Year 3 59.6% 53.1%

Year 4 45.3% 25.7%

Year 5 29.4% 14.7%

Year 10 20.7% 10.3%

Year 15 17.4% 8.7%

The conditional survival rates estimated by the integrated survival model at future time points given a patient has survived to 2 years.

TMZ: Maintenance temozolomide; TTFields: Tumor treating fields.